Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference23 articles.
1. ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study;Velasquez;J Clin Oncol,1994
2. ESHAP as salvage therapy for refractory non-Hodgkin’s lymphoma: Taiwan experience;Wang;Jpn J Clin Oncol,1999
3. Antiemetics: American Society of Clinical Oncology clinical practice guideline update;Basch;J Clin Oncol,2011
4. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy;Olver;Support Care Cancer,2013
5. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study;Adra;Support Care Cancer,2016
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study);eClinicalMedicine;2023-01
2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-11-16
3. Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study;Anti-Cancer Agents in Medicinal Chemistry;2021-11
4. Effect of different shielding conditions on the stability of Cisplatin;Journal of Pharmaceutical Health Care and Sciences;2020-03-11
5. Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey;Clinical Pharmacology: Advances and Applications;2019-11
Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3